Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries (Sun Pharma) and includes its subsidiaries and/or associate companies have entered into a worldwide license agreement on the development and commercialization of SCD044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other autoimmune disorders. SCD044 is entering phase 2 clinical trials.
Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of $20 million. SPARC will also be eligible to receive up to $125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
